Abstract:Fuchs'?endothelial?corneal?dystrophy?(FECD)?is?a?progressive?dystrophic?disease?characterized?by?gradual?damage?to?the?corneal?endothelium,?ultimately?leading?to?endothelial?decompensation.?The?current?standard?treatment,?corneal?transplantation,?has?several?limitations.?Recent?studies?have?shown?that?Rho-associated?kinase?(ROCK)?inhibitors?can?promote?cell?proliferation?by?modulating?the?Cyclin?D?and?p27?signaling?pathways.?Additionally,?ROCK?inhibitors?activate?Rac1,?which?drives?the?actin-related?protein?complex?(ARPC2)?to?enhance?cell?adhesion,?and?regulate?processes?such?as?membrane?blebbing,?nuclear?disintegration,?and?apoptotic?body?formation,?thereby?inhibiting?the?apoptosis?of?corneal?endothelial?cells.?These?findings?suggest?that?ROCK?inhibitors?may?be?a?promising?therapeutic?approach?for?FECD.?This?review?provides?an?overview?of?the?pharmacological?effects,?basic?research,?clinical?trials,?and?potential?adverse?reactions?associated?with?ROCK?inhibitors?in?the?treatment?of?FECD,?with?the?aim?of?developing?compounds?with?stable?efficacy?and?minimal?side?effects?for?the?treatment?of?FECD?in?the?near?future.
